Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Amicus Therapeutics (FOLD) Receivables - Net (2016 - 2025)

Amicus Therapeutics' Receivables - Net history spans 14 years, with the latest figure at $115.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net rose 14.05% year-over-year to $115.3 million, compared with a TTM value of $115.3 million through Dec 2025, up 14.05%, and an annual FY2025 reading of $115.3 million, up 14.05% over the prior year.
  • Receivables - Net for Q4 2025 was $115.3 million at Amicus Therapeutics, up from $113.8 million in the prior quarter.
  • The five-year high for Receivables - Net was $115.3 million in Q4 2025, with the low at $44.9 million in Q1 2021.
  • Average Receivables - Net over 5 years is $74.9 million, with a median of $70.8 million recorded in 2023.
  • Year-over-year, Receivables - Net grew 1.7% in 2022 and then surged 40.2% in 2023.
  • Tracing FOLD's Receivables - Net over 5 years: stood at $52.7 million in 2021, then grew by 25.68% to $66.2 million in 2022, then skyrocketed by 32.38% to $87.6 million in 2023, then increased by 15.37% to $101.1 million in 2024, then rose by 14.05% to $115.3 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Receivables - Net are $115.3 million (Q4 2025), $113.8 million (Q3 2025), and $105.8 million (Q2 2025).